NEW YORK, Jan. 9, 2024 /PRNewswire/ — The nontuberculous mycobacterial infections market is expected to grow by USD 4.33 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 5.66% during the forecast period, according to Technavio Research. The market is segmented by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), product (clarithromycin, azithromycin, rifampin, rifabutin, and others), and geography (North America, Europe, Asia, and the Rest of World (ROW)). North America is estimated to contribute 40% to the growth of the global market during the forecast period. The region boasts an advanced healthcare infrastructure, featuring cutting-edge diagnostic capabilities and a thriving pharmaceutical sector. The presence of state-of-the-art diagnostic tools, strong clinical research capacity, and a robust R&D ecosystem aids in identifying and comprehending NTM infections, fostering the advancement and acceptance of new therapies for NTM treatment.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report
Company Profile:
Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.
Astellas Pharma Inc. – The company offers nontuberculous mycobacterial infection drugs namely ASTAGRAF XL.
To gain access to more company profiles available with Technavio, buy the report!
Nontuberculous Mycobacterial Infections Market: Segmentation Analysis
The market share growth by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies provide essential intermediaries in the distribution of healthcare products, such as antibiotics and other medicinal products used for treating NTM infections.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report
Nontuberculous Mycobacterial Infections Market: Market Dynamics
Key Driver
The escalating prevalence of Nontuberculous Mycobacterial Infections (NTM), including Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium kansasii, Mycobacterium fortuitum, Mycobacterium chelonae, Mycobacterium xenopi, Mycobacterium malmoense, Mycobacterium intracellulare, and Mycobacterium genavense, stands as the primary driver boosting market expansion. This rise highlights the need for advanced therapies, diagnostics, and increased awareness, boosting market growth to combat the increasing burden of NTM infections globally.
Leading Trend
The prominent trend dictating the growth of the Nontuberculous Mycobacterial Infections (NTM) market involves the increasing embrace of precision medicine for addressing these infections. This trend is especially evident in the treatment of Mycobacterium simiae, Mycobacterium haemophilum, Mycobacterium marinum, Mycobacterium ulcerans, Mycobacterium gordonae, Mycobacterium szulgai, Mycobacterium scrofulaceum, Mycobacterium terrae, Mycobacterium celatum, and Mycobacterium xenopi. Precision medicine’s personalized approach signifies a pivotal shift driving advancements and tailored solutions in managing NTM infections, thereby steering market growth.
Significant Challenge
The diversity within Nontuberculous Mycobacterial Infections (NTM) strains is a significant challenge impacting market expansion. Mycobacterium immunogenum, Mycobacterium leprae, and the complexity of NTM strains associated with Nontuberculous Mycobacterial Lung Disease (NTM-LD), Bronchiectasis, Cystic Fibrosis, and Immunocompromised Patients present challenges. Issues such as Macrolide-resistant NTM, evolving Surgical Treatments, Antibiotic Therapy efficacy, and the need for advanced Diagnostic Tests compound the market’s complexities, influencing its growth trajectory.
Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The upper respiratory tract infection treatment market size is estimated to grow by USD 2,661.15 million at a CAGR of 4.21% between 2023 and 2028.
The Hospital Infection Therapeutics Market size is estimated to grow by USD 3,106.6 million at a CAGR of 4.98% between 2022 and 2027.
What are the key data covered in this Nontuberculous Mycobacterial Infections Market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the nontuberculous mycobacterial infections market between 2023 and 2028.
- Precise estimation of the nontuberculous mycobacterial infections market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the nontuberculous mycobacterial infections market across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of nontuberculous mycobacterial infections market companies.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Distribution Channel
Market Segmentation by Product
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
